Research Grade Risankizumab 研究级别药物对照抗体
一、中文名称：利散吉珠单抗
二、产品描述：Risankizumab (BI 655066) 是一种人源化 IgG 单克隆抗体，靶向 IL-23 p19 亚基(Kd <10 pM)，并能抑制人 IL-23 在小鼠脾细胞中诱导的 IL-17 产生(IC50 = 2 pM)。Risankizumab 可用于研究免疫性和炎症性疾病，如寻常型银屑病、银屑病关节炎、广泛性脓疱型银屑病和红皮病型银屑病
三、产品详情：
货号：DHJ63101
表达系统：Mammalian Cells
种属反应性：Human
宿主：Humanized
同种型：IgG1-kappa
克隆类型：Monoclonal
靶标：SGRF, IL-23-A, IL-23 subunit alpha, Interleukin-23 subunit p19, IL23A, Interleukin-23 subunit alpha, IL-23p19
浓度：5.1 mg/ml
内毒素水平：Please contact with the lab for this information.
纯度：>95% as determined by SDS-PAGE.
纯化方式：Protein A/G purified from cell culture supernatant.
Accession 号：Q9NPF7
克隆号：Risankizumab
应用：Research Grade Biosimilar
状态：Liquid
保存溶液：0.01M PBS, pH 7.4.
稳定性和存储：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
别名：BI 655066, risankizumab-rzaa, CAS: 1612838-76-2
四、参考文献：
Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. PMID: 37256136
The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. PMID: 33603597
Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta-analysis. PMID: 33140468
Systematic review and bayesian network meta-analysis: comparative efficacy and safety of six commonly used biologic therapies for moderate-to-severe Crohn's disease. PMID: 39911832
Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn's Disease: Systematic Review and Meta-Analysis. PMID: 37378711
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. PMID: Update in:
A network meta-analysis for the comparison of efficacy and safety of interleukin (IL)-23 targeted drugs in the treatment of moderate to severe psoriasis. PMID: 32521069
Nail psoriasis and nail lichen planus: Updates on diagnosis and management. PMID: 38007038
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). PMID: 37488811
AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. PMID: 39572132
Adverse Effects of Anti-Interleukin-23 Agents Employed in Patients with Psoriasis: A Systematic Review. PMID: 35697004
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. PMID: 39425738
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. PMID: 33349983
详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司
网址：https://www.biolabreagent.com/
武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。
试剂 | 耗材 | 定制 | 实验服务 | 供应链
免费热线：027-65279366 /18108604356
